<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1575">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028114</url>
  </required_header>
  <id_info>
    <org_study_id>AC-21-025</org_study_id>
    <nct_id>NCT05028114</nct_id>
  </id_info>
  <brief_title>Tricaprilin Liquid Formulation PK Study</brief_title>
  <official_title>A Phase 1, Three-part, Part-randomised, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Different Formulations of Tricaprilin, to Include Single-dose, Food Effect, and Titration Tolerability, in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerecin</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerecin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of&#xD;
      new liquid formulations of tricaprilin, with the aim of finding a suitable formulation to&#xD;
      advance in development. This is a three-part, part-randomised study that include single-dose,&#xD;
      food effect, and titration tolerability in up to 80 healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a three-part study.&#xD;
Part 1 (Formulation Optimisation): Participants will be assigned to all 4 different formulations of tricaprilin, with randomization to one of 4 sequences with a 2-day washout in between different formulations. There are 2 series in this part.&#xD;
Part 1 (Food Effect): Participants will be administered to 1 formulation of tricaprilin. There are 2 series in this part.&#xD;
Part 2 (Placebo Assessment): Participants will be randomised to 1 of 2 sequences (tricaprilin formulation - matching placebo; matching placebo - tricaprilin formulation) with a 2-day washout between periods.&#xD;
Part 3 (Titration Tolerability): Participants will be administered to either tricaprilin or a matching placebo.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of total ketones (β-hydroxybutyrate and acetoacetate) after single-dose administration of tricaprilin and placebo formulations (Part 1, Part 2)</measure>
    <time_frame>0 to 8 hours post-dose</time_frame>
    <description>AUC will be calculated from PK concentrations of total ketones (B-hydroxybutyrate and Acetoacetate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of total ketones (β-hydroxybutyrate and acetoacetate) after single-dose administration of tricaprilin and placebo formulations (Part 1, Part 2)</measure>
    <time_frame>0 to 8 hours post-dose</time_frame>
    <description>Cmax will be calculated from PK concentrations of total ketones (B-hydroxybutyrate and Acetoacetate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum concentration (Tmax) of total ketones (β-hydroxybutyrate and acetoacetate) after single-dose administration of tricaprilin and placebo formulations (Part 1, Part 2)</measure>
    <time_frame>0 to 8 hours post-dose</time_frame>
    <description>Tmax will be calculated from PK concentrations of total ketones (B-hydroxybutyrate and Acetoacetate)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>Baseline to end of treatment period</time_frame>
    <description>Adverse event incidence will be tabulated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal side effects of single-dose administration of each of tricaprilin formulations and the placebo formulation (Parts 1, 2) assessed using the Baxter Retching Faces Scale</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 3 hours post-dose</time_frame>
    <description>The Baxter Retching Faces Scale is a pictorial scale rated from 0 to 10, with 6 faces depicting level of nausea/gastrointestinal discomfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal side effects of single-dose administration of each of tricaprilin formulations and the placebo formulation (Parts 1, 2) assessed using the Pain Numerical Rating Scale</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 3 hours post-dose</time_frame>
    <description>The Pain Numerical Rating Scale 10-point numeric rating scale with participants instructed to rate any abdominal pain from 0 (no pain) to 10 (worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of total ketones (β-hydroxybutyrate and acetoacetate) of tricaprilin and placebo formulations following a titration scheme (Part 3)</measure>
    <time_frame>Days 15 and 21: 0 to 8 hours post-dose; Day 27: 0 to 24 hours post-dose</time_frame>
    <description>AUC will be calculated from PK concentrations of total ketones (B-hydroxybutyrate and Acetoacetate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of total ketones (β-hydroxybutyrate and acetoacetate) of tricaprilin and placebo formulations following a titration scheme (Part 3)</measure>
    <time_frame>Days 15 and 21: 0 to 8 hours post-dose; Day 27: 0 to 24 hours post-dose</time_frame>
    <description>Cmax will be calculated from PK concentrations of total ketones (B-hydroxybutyrate and Acetoacetate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (Tmax) of total ketones (β-hydroxybutyrate and acetoacetate) of tricaprilin and placebo formulations following a titration scheme (Part 3)</measure>
    <time_frame>Days 15 and 21: 0 to 8 hours post-dose; Day 27: 0 to 24 hours post-dose</time_frame>
    <description>Tmax will be calculated from PK concentrations of total ketones (B-hydroxybutyrate and Acetoacetate)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Part 1 (Formulation Optimisation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided 30 minutes after study drug administration. There will be 4 different formulations of the study drug and participants will be randomised to one of 4 sequences. There will be a washout of 2 days between each administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Placebo Assessment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided either 30 minutes before or after study drug administration, depending on the results of the food effect assessment.&#xD;
Participants are randomised to 1 of 2 sequences (tricaprilin formulation - matching placebo; matching placebo - tricaprilin formulation) with a 2-day washout between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 (Titration Tolerability)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided either 30 minutes before or after study drug administration, depending on the results of the food effect assessment.&#xD;
Participants will be randomised to either study drug or the matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-1202</intervention_name>
    <description>Tricaprilin formulated as AC-1202</description>
    <arm_group_label>Part 1 (Formulation Optimisation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-OLE-01</intervention_name>
    <description>Tricaprilin Formulation</description>
    <arm_group_label>Part 1 (Formulation Optimisation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-OLE-02</intervention_name>
    <description>Tricaprilin Formulation</description>
    <arm_group_label>Part 1 (Formulation Optimisation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-OLE-03</intervention_name>
    <description>Tricaprilin Formulation</description>
    <arm_group_label>Part 1 (Formulation Optimisation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-OLE-04</intervention_name>
    <description>Tricaprilin Formulation</description>
    <arm_group_label>Part 1 (Formulation Optimisation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-OLE-05</intervention_name>
    <description>Tricaprilin Formulation</description>
    <arm_group_label>Part 1 (Formulation Optimisation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-OLE-06</intervention_name>
    <description>Tricaprilin Formulation</description>
    <arm_group_label>Part 1 (Formulation Optimisation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-OLE-07</intervention_name>
    <description>Tricaprilin Formulation</description>
    <arm_group_label>Part 1 (Formulation Optimisation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-OLE-08</intervention_name>
    <description>Tricaprilin Formulation</description>
    <arm_group_label>Part 1 (Formulation Optimisation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-OLE-09</intervention_name>
    <description>Tricaprilin Formulation</description>
    <arm_group_label>Part 1 (Formulation Optimisation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-OLE-010</intervention_name>
    <description>Tricaprilin Formulation</description>
    <arm_group_label>Part 1 (Formulation Optimisation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-OLE-P</intervention_name>
    <description>Placebo to tricaprilin formulation</description>
    <arm_group_label>Part 2 (Placebo Assessment)</arm_group_label>
    <arm_group_label>Part 3 (Titration Tolerability)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 to 65 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Participants who are overtly healthy (in the opinion of the Investigator) as&#xD;
             determined by medical evaluation including medical history, physical examination,&#xD;
             laboratory tests, and cardiac monitoring&#xD;
&#xD;
          -  Body weight ≥45 kg and body mass index (BMI) within the range 18.0 - 32.0 kg/m2&#xD;
             (inclusive).&#xD;
&#xD;
          -  Male and female&#xD;
&#xD;
          -  Agrees to comply with study procedures including blood draws, confinement to clinic,&#xD;
             meal requirements&#xD;
&#xD;
          -  Continuous non-smoker or infrequent smoker (no more than 10 cigarettes per week for at&#xD;
             least 3 months prior to Screening)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of, or current gastrointestinal (GI) conditions constituting a risk when&#xD;
             taking the study treatment; or interfering with the interpretation of data, based on&#xD;
             the Investigator's judgement&#xD;
&#xD;
          -  Past or intended use of over-the-counter or prescription medication including herbal&#xD;
             medications within 7 days prior to dosing (paracetamol/acetaminophen [up to 2 g per&#xD;
             day], hormone replacement therapy and hormonal contraception are permitted).&#xD;
&#xD;
          -  Participants on a ketogenic diet, low-fat diet or actively using medium chain&#xD;
             triglycerides, ketone esters, or other ketogenic products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Cerecin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>+65 6813 2999</phone>
    <email>clinicaltrials@cerecin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Harris</last_name>
      <phone>+61 08 7088 7900</phone>
      <email>cmax@cmax.com.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

